Literature DB >> 16716880

Hyperuricemia and associated diseases.

Michael A Becker1, Meenakshi Jolly.   

Abstract

After introduction of urate-lowering therapy, asympotomatic hyperuricemia was treated with allopurinol or uricosuric agents in the belief that hyperuricemia and/or gout caused chronic kidney disease. Epidemiologic studies in the 1970s, however, failed to confirm the view that hyperuricemia and gout were independent risk factors for chronic kidney disease. As a result, urate-lowering pharmacotherapy is generally not recommended at the present time in the management of asymptomatic hyperuricemia even though recent epidemiological, experimental, and clinical studies have prompted reexamination of a causal role for hyperuricemia (with or without gout) in chronic kidney disease as well as other important disorders including cardiovascular disease, hypertension, and metabolic syndrome. The issue of such a role remains unresolved and this article reviews the current status of the relationship between hyperuricemia and associated disorders.

Entities:  

Mesh:

Year:  2006        PMID: 16716880     DOI: 10.1016/j.rdc.2006.02.005

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  29 in total

1.  Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.

Authors:  Brian Grabowski; Reza Khosravan; Jing-Tao Wu; Laurent Vernillet; Christopher Lademacher
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 2.  Hyperuricemia and risk of stroke: a systematic review and meta-analysis.

Authors:  Seo Young Kim; James P Guevara; Kyoung Mi Kim; Hyon K Choi; Daniel F Heitjan; Daniel A Albert
Journal:  Arthritis Rheum       Date:  2009-07-15

3.  Developing potent human uric acid transporter 1 (hURAT1) inhibitors.

Authors:  Michael F Wempe; Promsuk Jutabha; Bettina Quade; Timothy J Iwen; Morin M Frick; Ian R Ross; Peter J Rice; Naohiko Anzai; Hitoshi Endou
Journal:  J Med Chem       Date:  2011-03-30       Impact factor: 7.446

4.  Gender-specific risk factors for incident gout: a prospective cohort study.

Authors:  Jiunn-Horng Chen; Wen-Ting Yeh; Shao-Yuan Chuang; Yi-Ying Wu; Wen-Harn Pan
Journal:  Clin Rheumatol       Date:  2011-07-15       Impact factor: 2.980

5.  Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter.

Authors:  Masafumi Iharada; Takaaki Miyaji; Takahiro Fujimoto; Miki Hiasa; Naohiko Anzai; Hiroshi Omote; Yoshinori Moriyama
Journal:  J Biol Chem       Date:  2010-06-21       Impact factor: 5.157

Review 6.  Hyperuricemia and coronary heart disease: a systematic review and meta-analysis.

Authors:  Seo Young Kim; James P Guevara; Kyoung Mi Kim; Hyon K Choi; Daniel F Heitjan; Daniel A Albert
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-02       Impact factor: 4.794

7.  Relevance of uric Acid in progression of type 2 diabetes mellitus.

Authors:  Adlija Causevic; Sabina Semiz; Amra Macic Dzankovic; Bakira Cico; Tanja Dujic; Maja Malenica; Tamer Bego
Journal:  Bosn J Basic Med Sci       Date:  2010-02       Impact factor: 3.363

8.  The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.

Authors:  Michael A Becker; H Ralph Schumacher; Luis R Espinoza; Alvin F Wells; Patricia MacDonald; Eric Lloyd; Christopher Lademacher
Journal:  Arthritis Res Ther       Date:  2010-04-06       Impact factor: 5.156

9.  Relationship between hyperuricemia and metabolic syndrome.

Authors:  Li-ying Chen; Wen-hua Zhu; Zhou-wen Chen; Hong-lei Dai; Jing-jing Ren; Jian-hua Chen; Lei-qian Chen; Li-zheng Fang
Journal:  J Zhejiang Univ Sci B       Date:  2007-08       Impact factor: 3.066

10.  Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes.

Authors:  Suzan Wopereis; Carina M Rubingh; Marjan J van Erk; Elwin R Verheij; Trinette van Vliet; Nicole H P Cnubben; Age K Smilde; Jan van der Greef; Ben van Ommen; Henk F J Hendriks
Journal:  PLoS One       Date:  2009-02-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.